|
ANABONOS - MOLECULAR MECHANISMS OF BONE FORMATION AND ANABOLISM (Life sciences, genomics and biotechnology for health) (2004-03-01 - 2007-08-31)
(»add to infobox)
| ACRONYM: | ANABONOS |
| BUDGET: | 4.615.280 € |
| FUNDING: | 3.000.000 € |
| INSTRUMENT: | Specific Targeted Research Project |
| PROGRAMME: | Life sciences, genomics and biotechnology for health |
 |
|
|
Osteoporotic fractures are a major healthcare problem in Europe and this is set to increase as the proportion of the elderly individuals in the population expands. Osteoporosis can be treated by drugs that inhibit bone résorption, but these do not restore normal skeletal strength and are incompletely effective at preventing fractures. Consequently, there is an urgent need to develop new treatments for osteoporosis that stimulate bone formation. Such treatments would offer the prospect of greater efficacy by reversing the structural abnormalities of bone in established osteoporosis. This proposal will advance understanding of the mechanisms responsible for bone formation, with the long-term aim of harnessing this knowledge to develop new anabolic agents for osteoporosis. These aims will be achieved by drawing leading European academic research groups together with SME's working in bone metabolism to define the mechanisms of bone formation and uncover pathways that can be targeted for therapeutic intervention. We will define downstream effectors of molecules which regulate bone formation in mice and define signalling pathways that are activated in human genetic diseases characterised by increased bone formation. The mechanisms of action for drugs with known anabolic effects will be investigated and novel genes which regulate bone formation uncovered by END mutagenesis and genetic mapping in mice. Finally, a technology based on atomic force microscopy (AFM) will be developed to study anabolic effects in osteoblasts in response to mechanical force and anabolic agents. The proposal will lead to a greater understanding of how bone formation is regulated and will underpin the development of new therapeutic strategies for the prevention and treatment of osteoporosis.'
Keywords:
bone disease, osteoporosis, fracture,
|
| COORDINATOR (1/1) |
|
Stuart Hamilton RALSTON (Contact / UNIVERSITY OF ABERDEEN (UKM10 - Aberdeen City, Aberdeenshire and North East Moray) (UK - Great Britain))
| PARTICIPANTS (12/12) |
|
Wim VAN HUL (Contact / UNIVERSITEIT ANTWERPEN (BE211 - Arr. Antwerpen) (BE - Belgium))
Monique FRAIN (Contact / INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR101 - Paris) (FR - France))
Giovanni LEVI (Contact / CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR101 - Paris) (FR - France))
Clemens W. G. M. LOWIK (Contact / AKADEMISCH ZIEKENHUIS LEIDEN - LEIDEN UNIVERSITAIR MEDISCH CENTRUM (NL331 - Agglomeratie Leiden en Bollenstreek) (NL - Netherlands))
Teresa GARCIA (Contact / PROSKELIA SAS (FR106 - Seine-Saint-Denis) (FR - France))
Agi GRIGORIADIS (Contact / KING'S COLLEGE LONDON (UKI11 - Inner London - West) (UK - Great Britain))
Frank GANNON (Contact / EUROPAISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE - EMBL (DE125 - Heidelberg, Stadtkreis) (DE - Germany))
Erwin WAGNER (Contact / FORSCHUNGSINSTITUT FUER MOLEKULARE PATHOLOGIE GESMBH (AT130 - Wien) (AT - Austria))
Johannes GROSSE (Contact / INGENIUM PHARMACEUTICALS AG (DE21 - Oberbayern) (DE - Germany))
Serge FERRARI (Contact / UNIVERSITE DE GENEVE (CH012 - Valais) (CH - Switzerland))
Stefan MUNDLOS (Contact / MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV (DE212 - München, Kreisfreie Stadt) (DE - Germany))
Martin HRABE DE ANGELIS (Contact / GSF - FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GMBH (DE21 - Oberbayern) (DE - Germany))
| RELATED THEMATIC AREAS (1/1) |
|
Studying human development and the ageing process
|
|
|
LifeCompetence operated by AVEDAS
Contact: support@avedas.com
|
